Moderna agreed to settle long‑running patent claims over its Covid‑19 vaccine by paying $950 million upfront to Arbutus Biopharma and Roivant’s Genevant, with contingent payments that could push total liabilities higher if legal appeals leave federal cost‑sharing unresolved. The settlement resolves a multiyear dispute over lipid nanoparticle and delivery patents central to mRNA vaccine formulations. Legal analysts described the payout as among the largest patent settlements in biotech, with downstream implications for how platform IP is monetized and litigated. The agreement removes a major uncertainty for Moderna’s balance sheet but highlights the exposure vaccine platform developers face from foundational delivery‑technology patents.